Table 3.
Characteristics of the patients at the time of malignancies' diagnosis for AIDS-defining malignancies (ADMs) versus non-AIDS-defining malignancies (NADMs). Factors statistically associated with NADMs in bold
| Characteristic | ADMs | NADMs | OR | 95% CI | p value | |||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| n | % | n | % | |||||
| Sex | female | 53 | 33.3 | 27 | 20.9 | 1 | - | - |
| male | 106 | 66.7 | 102 | 79.1 | 1.889 | 1.104-3.233 | 0.024 | |
| Age at the malignancies' diagnosis (years) | [20; 30) | 34 | 21.4 | 18 | 14.0 | 1 | - | - |
| [30; 40) | 65 | 40.9 | 22 | 17.1 | 0.639 | 0.302-1.351 | 0.252 | |
| [40; 50) | 38 | 23.9 | 41 | 31.8 | 2.038 | 0.99-4.195 | 0.072 | |
| [50; 60) | 20 | 12.6 | 32 | 24.8 | 3.022 | 1.359-6.72 | 0.01 | |
| [60; 81] | 2 | 01.3 | 16 | 12.4 | 15.111 | 3.122-73.151 | 0 | |
| Mode of HIV exposure | bisexual | 6 | 03.8 | 7 | 05.4 | 1 | - | - |
| heterosexual | 38 | 23.9 | 32 | 24.8 | 0.722 | 0.22-2.367 | 0.764 | |
| IDU | 54 | 34.0 | 55 | 42.6 | 0.873 | 0.276-2.766 | 1 | |
| MSM | 61 | 38.4 | 35 | 27.1 | 0.492 | 0.153-1.58 | 0.241 | |
| Duration of HIV-infection at the malignancies' diagnosis (years) | [0; 1) | 66 | 41.5 | 24 | 18.6 | 1 | - | - |
| [1; 5) | 39 | 24.5 | 35 | 27.1 | 2.468 | 1.284-4.742 | 0.009 | |
| [5; 10) | 26 | 16.4 | 27 | 20.9 | 2.856 | 1.4-5.826 | 0.004 | |
| [10; 34] | 28 | 17.6 | 43 | 33.3 | 4.223 | 2.168-8.228 | 0 | |
| Opportunistic infections before malignancies' diagnosis | no | 98 | 61.6 | 63 | 48.8 | 1 | - | - |
| yes | 61 | 38.4 | 66 | 51.2 | 1.683 | 1.051-2.694 | 0.032 | |
| Nadir CD4 count (cells/mm3) | [0; 200) | 126 | 79.2 | 93 | 72.1 | 1 | - | - |
| [200; 350) | 21 | 13.2 | 24 | 18.6 | 1.548 | 0.813-2.948 | 0.191 | |
| [350; 500) | 8 | 05.0 | 6 | 04.7 | 1.016 | 0.341-3.028 | 1 | |
| [> 500] | 4 | 02.5 | 6 | 04.7 | 2.032 | 0.558-7.407 | 0.336 | |
| Smoking status | no | 45 | 28.3 | 27 | 20.9 | 1 | - | - |
| yes | 114 | 71.7 | 102 | 79.1 | 1.491 | 0.863-2.576 | 0.172 | |
| Alcohol status | no | 85 | 53.5 | 74 | 57.4 | 1 | - | - |
| yes | 74 | 46.5 | 55 | 42.6 | 0.854 | 0.535-1.363 | 0.552 | |
| Drugs status | no | 102 | 64.2 | 74 | 57.4 | 1 | - | - |
| yes | 57 | 35.8 | 55 | 42.6 | 1.33 | 0.826-2.141 | 0.274 | |
| Hepatitis C status | negative | 97 | 61.0 | 70 | 54.3 | 1 | - | - |
| positive | 58 | 36.5 | 58 | 45.0 | 1.386 | 0.861-2.231 | 0.184 | |
| unknown | 4 | 02.5 | 1 | 00.8 | 0.346 | 0.038-3.167 | 0.65 | |
| Hepatitis B status | negative | 107 | 67.3 | 75 | 58.1 | 1 | - | - |
| positive | 51 | 32.1 | 54 | 41.9 | 1.511 | 0.932-2.449 | 0.109 | |
| unknown | 1 | 00.6 | 0 | 0.00 | 0 | 0-NaN | 1 | |
| CD4+ count at the malignancies' diagnosis (cells/mm3) | [3; 51) | 38 | 23.9 | 15 | 11.6 | 1 | - | - |
| [51; 501) | 102 | 64.2 | 81 | 62.8 | 2.012 | 1.035-3.912 | 0.04 | |
| [> 501] | 19 | 11.9 | 33 | 25.6 | 4.4 | 1.934-10.011 | 0 | |
| cART before malignancies' diagnosis | no | 89 | 56.0 | 49 | 38.0 | 1 | - | - |
| yes | 70 | 44.0 | 80 | 62.0 | 2.076 | 1.293-3.334 | 0.003 | |
| VL suppression at the malignancies' diagnosis | no | 121 | 76.1 | 69 | 53.5 | 1 | - | - |
| yes | 38 | 23.9 | 60 | 46.5 | 2.769 | 1.675-4.577 | 0 | |
| Death during study period | no | 93 | 58.5 | 65 | 50.4 | 1 | - | - |
| yes | 66 | 41.5 | 64 | 49.6 | 1.387 | 0.869-2.214 | 0.191 | |
| Overall survival after malignancies' diagnosis (years) | [0; 1) | 55 | 34.6 | 44 | 34.1 | 1 | - | - |
| [1; 2) | 13 | 08.2 | 20 | 15.5 | 1.923 | 0.862-4.293 | 0.114 | |
| [2; 5) | 42 | 26.4 | 38 | 29.5 | 1.131 | 0.626-2.043 | 0.763 | |
| [5; 10) | 27 | 17.0 | 23 | 17.8 | 1.065 | 0.538-2.108 | 0.863 | |
| [10; 17] | 22 | 13.8 | 4 | 03.1 | 0.227 | 0.073-0.708 | 0.007 | |
OR – odds ratio; 95% CI – 95% confidence limits; cART – combination antiretroviral therapy; VL – viral load